Beam Therapeutics Inc., founded in 2017 and based in Cambridge, Massachusetts, operates as a pioneering biopharmaceutical firm. Its core mission involves engineering precise genetic remedies to tackle a spectrum of severe human ailments, primarily within the United States. The company's developmental portfolio features several key candidates: BEAM-101 is being advanced to treat both sickle cell disease and beta thalassemia. BEAM-102 is specifically designed for addressing sickle cell disease. BEAM-201, an allogeneic chimeric antigen receptor T-cell therapy, is under investigation for…
$PRME $BEAM https://t.co/cxLO1AEY8v
15 analysts rate BEAM Buy on consensus.
Consensus price target: $52.15 (+116.84% upside from $24.05)
| Insider | Date | Transaction | Shares | Value |
|---|---|---|---|---|
| Evans John M. director, CEO | Oct 16, 2026 | Sale | 25,000 | $599.6K |
| Evans John M. director, CEO | Oct 15, 2026 | Sale | 25,000 | $589.15K |
| Cavanagh Bethany J SVP, Finance and Treasurer | Oct 1, 2026 | Sale | 187 | $4.56K |
| Simon Amy Chief Medical Officer | Jul 27, 2026 | Sale | 16,667 | $429.04K |
| Evans John M. director, CEO | Jun 30, 2026 | Sale | 1,900 | $66.2K |
| Fiscal year | Revenue | Revenue YoY | Net income |
|---|---|---|---|
| 2025 | $139.74M | +120.01% | $-79.99M |
| 2024 | $63.52M | -83.18% | $-376.74M |
| 2023 | $377.71M | +520.01% | $-132.53M |
Stock data for BEAM: Summary · AI Insight · Feed · News · Financials · Transcript · SEC Filings · Insider · Politics